de Groot A N, van Roosmalen J, van Dongen P W, Borm G F
Department of Obstetrics & Gynaecology, Catharina Hospital, Eindhoven, The Netherlands.
Acta Obstet Gynecol Scand. 1996 May;75(5):464-8. doi: 10.3109/00016349609033355.
Active management with oral ergometrine 0.4 mg was compared with expectant management for the control of blood loss in the third stage of labor in women at low risk of postpartum hemorrhage (PPH).
A three-arms randomized trial in which 0.4 mg ergometrine (2 tablets of 0.2 mg) was set off against placebo, both groups allowing comparison with a standard oxytocin regimen of 5 IU. Women at low risk for PPH. Of 367 parturients, 146 were randomised to ergometrine 0.4 mg, 143 to placebo and 78 to intramuscular oxytocin in a 2:2:1 design.
Compared with placebo, ergometrine reduced blood loss with 5% (-5%; Confidence interval: -20% to +13%). Oxytocin reduced blood loss with 9% (-9%; Confidence interval: -26% to +12%) versus placebo.
Oral ergometrine has too little effect on blood loss after childbirth in order to be a good alternative to parenteral prophylactic management.
将口服0.4毫克麦角新碱的积极管理与期待性管理相比较，以控制产后出血（PPH）低风险女性分娩第三阶段的失血情况。
一项三臂随机试验，其中0.4毫克麦角新碱（两片0.2毫克）与安慰剂对照，两组均可与5国际单位的标准催产素方案进行比较。PPH低风险女性。在367名产妇中，146名按2:2:1的设计随机分配至0.4毫克麦角新碱组，143名至安慰剂组，78名至肌内注射催产素组。
与安慰剂相比，麦角新碱使失血量减少了5%（-5%；置信区间：-20%至+13%）。与安慰剂相比，催产素使失血量减少了9%（-9%；置信区间：-26%至+12%）。
口服麦角新碱对产后失血的影响太小，无法成为肠外预防性管理的良好替代方案。
